Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MXCT - US57777K1060 - Common Stock

1.23 USD
+0.02 (+1.65%)
Last: 1/21/2026, 8:00:01 PM
1.24 USD
+0.01 (+0.81%)
After Hours: 1/21/2026, 8:00:01 PM
Fundamental Rating

3

Overall MXCT gets a fundamental rating of 3 out of 10. We evaluated MXCT against 57 industry peers in the Life Sciences Tools & Services industry. While MXCT has a great health rating, there are worries on its profitability. MXCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MXCT has reported negative net income.
  • In the past year MXCT has reported a negative cash flow from operations.
  • In the past 5 years MXCT always reported negative net income.
  • MXCT had a negative operating cash flow in each of the past 5 years.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • MXCT's Return On Assets of -21.38% is on the low side compared to the rest of the industry. MXCT is outperformed by 66.67% of its industry peers.
  • MXCT has a Return On Equity of -25.31%. This is comparable to the rest of the industry: MXCT outperforms 43.86% of its industry peers.
Industry RankSector Rank
ROA -21.38%
ROE -25.31%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • MXCT's Gross Margin of 79.97% is amongst the best of the industry. MXCT outperforms 100.00% of its industry peers.
  • MXCT's Gross Margin has declined in the last couple of years.
  • MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

  • MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MXCT has been increased compared to 1 year ago.
  • Compared to 5 years ago, MXCT has more shares outstanding
  • MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • MXCT has an Altman-Z score of 0.72. This is a bad value and indicates that MXCT is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.72, MXCT is doing worse than 66.67% of the companies in the same industry.
  • MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.72
ROIC/WACCN/A
WACC11.12%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • MXCT has a Current Ratio of 7.74. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
  • MXCT has a better Current ratio (7.74) than 89.47% of its industry peers.
  • A Quick Ratio of 7.27 indicates that MXCT has no problem at all paying its short term obligations.
  • The Quick ratio of MXCT (7.27) is better than 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 7.74
Quick Ratio 7.27
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

  • MXCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.59%.
  • The Revenue for MXCT has decreased by -24.52% in the past year. This is quite bad
  • The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)-24.52%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%

3.2 Future

  • Based on estimates for the next years, MXCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.36% on average per year.
  • Based on estimates for the next years, MXCT will show a very strong growth in Revenue. The Revenue will grow by 20.40% on average per year.
EPS Next Y-4.09%
EPS Next 2Y13.36%
EPS Next 3Y12.98%
EPS Next 5Y11.36%
Revenue Next Year-6.51%
Revenue Next 2Y1.94%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • MXCT's earnings are expected to grow with 12.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.36%
EPS Next 3Y12.98%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MXCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAXCYTE INC

NASDAQ:MXCT (1/21/2026, 8:00:01 PM)

After market: 1.24 +0.01 (+0.81%)

1.23

+0.02 (+1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-12
Earnings (Next)05-04
Inst Owners70.4%
Inst Owner Change0.03%
Ins Owners1.32%
Ins Owner Change2.81%
Market Cap131.20M
Revenue(TTM)34.42M
Net Income(TTM)-45.63M
Analysts83.08
Price Target6.47 (426.02%)
Short Float %2.38%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.97%
Min EPS beat(2)-13.86%
Max EPS beat(2)19.79%
EPS beat(4)3
Avg EPS beat(4)8.05%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.79%
EPS beat(8)7
Avg EPS beat(8)17.39%
EPS beat(12)9
Avg EPS beat(12)13.75%
EPS beat(16)13
Avg EPS beat(16)15.62%
Revenue beat(2)0
Avg Revenue beat(2)-16.24%
Min Revenue beat(2)-20.01%
Max Revenue beat(2)-12.47%
Revenue beat(4)2
Avg Revenue beat(4)-4.92%
Min Revenue beat(4)-20.01%
Max Revenue beat(4)7.51%
Revenue beat(8)6
Avg Revenue beat(8)10.53%
Revenue beat(12)7
Avg Revenue beat(12)4.03%
Revenue beat(16)11
Avg Revenue beat(16)5.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.53%
EPS NY rev (1m)0%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)4.11%
Revenue NY rev (1m)-0.44%
Revenue NY rev (3m)-2.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.81
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.32
BVpS1.69
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.38%
ROE -25.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.97%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.94%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.74
Quick Ratio 7.27
Altman-Z 0.72
F-Score2
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-4.09%
EPS Next 2Y13.36%
EPS Next 3Y12.98%
EPS Next 5Y11.36%
Revenue 1Y (TTM)-24.52%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%
Revenue Next Year-6.51%
Revenue Next 2Y1.94%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%
EBIT growth 1Y-7.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.57%
EBIT Next 3Y15.85%
EBIT Next 5Y12.68%
FCF growth 1Y-22.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.54%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


Can you provide the valuation status for MAXCYTE INC?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


How profitable is MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.